Skip to main content
TipRanks
Go Ultimate75% OFF

Xvivo Perfusion AB (XVIVO) AI Stock Analysis

4 Followers
SE:XVIVO

Xvivo Perfusion AB

(Nasdaq OMX AB:XVIVO)

Select Model
Rating:64Neutral
Price Target:SEK 220.00▲(11.56% Upside)
Action:reiterated
Date:10/24/26

The score is driven primarily by solid fundamentals—especially a very strong, low-debt balance sheet and improved recent profitability/cash generation—plus a constructive earnings call highlighting strong growth and regulatory progress. These positives are meaningfully offset by weak technicals (price below key moving averages with negative MACD) and a demanding valuation (P/E ~50), alongside near-term execution risks (component constraints, services weakness, and expected margin pressure from planned investment).

Positive Factors
Strong organic growthThe broad-based growth indicates rising adoption of XVIVO’s transplantation technologies, especially in thoracic procedures. Strong sales expansion across the first nine months supports operating leverage, funds continued commercial investment, and strengthens the company’s position as transplant centers adopt advanced preservation workflows.
Negative Factors
Component constraintsComponent shortages directly limit the company’s ability to convert customer demand into revenue, particularly in kidney products. Although management describes the issue as temporary, continued constraints over coming quarters could delay growth, weaken customer availability, and postpone the return to higher growth rates.

Xvivo Perfusion AB (XVIVO) vs. iShares MSCI Sweden ETF (EWD)

0%20%40%60%80%100%SE:XVIVO+19.88%EWD+16.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 598.49M
Dividend Yield
―
Average Volume (3M)
80.72K
Price to Earnings (P/E)
48.2
Beta (1Y)
1.25
Revenue Growth
17.83%
EPS Growth
330.94%
Country
Sweden
Employees
207
Sector
General
Sector Strength
55
Industry
Medical - Devices

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across S...

How the Company Makes Money

XVIVO primarily makes money by selling transplantation-related products to healthcare customers involved in organ transplantation (e.g., transplant centers, hospitals, and organ procurement-related organizations). Key revenue streams include: (1) sal...

Xvivo Perfusion AB Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:-12.97%|Next Earnings Date:Jan 28, 2027
Earnings Call SentimentPositive

The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.

Positive Updates

Strong Q3 Revenue and EBITDA Growth
Q3 net sales reached SEK 253 million, representing 32% organic growth in local currencies. EBITDA increased to SEK 52 million from SEK 36 million, and the EBITDA margin improved to 21% from 19%, supported primarily by strong sales and seasonally lower summer activity levels on the cost side.

Negative Updates

Temporary Headwind from Component Transition
Sales in the current and coming quarters will be affected by the transition to updated core components. Management described this as a temporary headwind, and stated that component shortages will prevent XVIVO from fulfilling the full market demand for kidney products next year.

Company Guidance

Management said kidney growth would be “moderate growth, probably around 30%” next year, although component shortages mean XVIVO “will not be able to fulfill the full demand of the market next year in kidney,” with growth expected to “return to higher levels of growth from the beginning of 2027”; service growth in 2027 is “very reasonable to expect,” “not necessarily in Q4”; new lung customer growth will “hopefully cover any shortfall,” which is the “working hypothesis right now”; static cold storage growth is expected to be “roughly 5% for next year”; Tier 2 heart customers are targeted for onboarding in December, with a “three to four months” listing process; the U.S. Heart Assist Transport commercial launch is targeted for “late 2027,” subject to the FDA review process and approval; Liver Assist is targeted for a 510(k) submission in “the first half of 2027” and a commercial launch in “early 2028,” subject again to regulatory timelines; and management expects “a slight margin dip during the second half of the year” from increased sales-force investment.

Xvivo Perfusion AB Financial Statement Overview

Summary

Strong balance sheet (very low leverage with ~0.06 debt-to-equity) and improved TTM profitability and cash conversion support the score. Offsetting this, profitability has been volatile (notable margin step-down from 2024 levels) and free cash flow consistency remains a concern after multiple prior years of negative FCF.

Income Statement

78Positive

Balance Sheet

87Very Positive

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue958.65M812.16M822.41M597.54M415.29M258.39M
Gross Profit614.41M533.50M616.41M445.11M296.96M188.28M
EBITDA214.12M153.14M272.97M35.05M65.58M39.20M
Net Income128.85M25.16M172.18M91.82M18.43M8.15M
Balance Sheet
Total Assets2.59B2.37B2.40B2.20B1.73B1.54B
Cash, Cash Equivalents and Short-Term Investments313.24M292.09M415.52M546.09M246.54M398.70M
Total Debt120.61M124.72M34.04M31.44M10.01M5.72M
Total Liabilities323.02M260.65M245.97M250.57M302.95M257.15M
Stockholders Equity2.27B2.11B2.16B1.95B1.43B1.29B
Cash Flow
Free Cash Flow191.56M-151.84M-81.86M-97.65M-103.09M-106.13M
Operating Cash Flow268.77M101.07M111.29M46.29M27.86M-12.06M
Investing Cash Flow-237.79M-258.41M-243.81M-161.62M-197.62M-187.70M
Financing Cash Flow-11.14M72.25M-10.90M418.55M-6.84M234.61M

Xvivo Perfusion AB Technical Analysis

Technical Analysis SentimentNegative
Last Price197.20

Price Trends

50DMA219.58Negative
100DMA243.91Negative
200DMA242.84Negative

Market Momentum

MACD-6.18Negative
RSI38.49Neutral
STOCH24.26Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Negative. The current price of 197.20 is below the 20-day moving average (MA) of 202.56, below the 50-day MA of 219.58, and below the 200-day MA of 242.84, indicating a bearish trend. The MACD of -6.18 indicates Negative momentum. The RSI at 38.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XVIVO.

Xvivo Perfusion AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:XVIVO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.72B26.769.13%1.71%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.21B48.225.89%―17.83%330.94%
SE:VITRSE:VITR63NeutralSEK 15.94B-3.21-61.57%0.93%-1.94%-1223.74%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:SEDANASE:SEDANA49NeutralSEK 883.11M-25.59-3.88%―0.42%15.03%
SE:BICOSE:BICO40UnderperformSEK 1.10B-5.05-28.59%―-5.27%34.38%
SE:SCIBSE:SCIB40UnderperformSEK 128.49M-0.68-415.20%―54.94%47.64%

* General Sector Average

Performance Comparison

-50%0%50%100%150%SE:XVIVOSE:GETI.BSE:VITRSE:BICOSE:SCIBSE:SEDANADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:XVIVO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:XVIVOXvivo Perfusion AB197.2031.6019.08%
SE:GETI.BGetinge AB (UK)278.0076.3537.86%
SE:VITRVitrolife AB117.70-22.75-16.20%
SE:BICOBICO Group AB Class B16.30-2.01-10.98%
SE:SCIBSciBase Holding AB9.10-9.99-52.34%
SE:SEDANASedana Medical AB8.89-0.74-7.68%

Xvivo Perfusion AB Corporate Events

Xvivo Perfusion Boosts Sales and Profit as Heart R&D Spend Rises

Oct 22, 2026

Xvivo Perfusion AB reported robust third-quarter 2026 performance, with net sales rising 34 percent to SEK 252.6 million driven by 32 percent organic growth in local currencies. Thoracic and abdominal product sales saw strong double-digit increases,...

XVIVO Perfusion Sets October 22 Call for Q3 2026 Interim Report

Oct 14, 2026

XVIVO Perfusion AB has scheduled a conference call to discuss its interim report for the July–September 2026 period, reinforcing its communication with investors and analysts in the transplantation-focused medtech sector. The presentation, led by CEO...

XVIVO Perfusion Sets 2027 Nomination Committee and Invites Shareholder Input

Sep 30, 2026

The following members have been appointed to XVIVO Perfusion’s nomination committee ahead of the 2027 annual general meeting: Henrik Blomquist, representing Bure Equity AB; Thomas Ehlin, representing The Fourth Swedish National Pension Fund; Martin L...

XVIVO Files FDA PMA for Heart Assist Transport System After Key U.S. Trial

Sep 28, 2026

XVIVO Perfusion AB has submitted a Premarket Approval application to the U.S. Food and Drug Administration for its XVIVO Heart Assist Transport System, supported by data from the 141-patient PRESERVE IDE trial at 14 leading U.S. heart transplant cent...

XVIVO Wins CE Mark for Heart Preservation System, Expanding European Transplant Access

Aug 11, 2026

XVIVO Perfusion has secured CE certificates for its XVIVO Heart Assist Transport system, a hypothermic oxygenated perfusion-based technology designed to preserve donor hearts in an oxygen-rich, controlled environment. This approval makes the system i...

XVIVO Wins Expanded U.S. Enrollment for Heart Transport Trial

Aug 3, 2026

XVIVO Perfusion AB has secured U.S. regulatory clearance to enroll an additional 60 patients in the PRESERVE Continued Access Protocol study for its investigational XVIVO Heart Assist Transport device, following completion of the initial cohort acros...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026